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phase II in fixed effect regression models to estimate the ef-
fect of incontinence on caring costs for UI.
RESULTS: Compared with long-term care residents with-
out UI, those with occasional UI consumed $2.90 more
per shift on labor and supply costs, while those with fre-
quent UI consumed $5.76 more. Incremental laundry costs
per shift are $0.34. Our study suggests that, on average,
the increased cost of caring for a UI patient in a long term
care facility is $5,650 per year, after controlling for factors
such as patient demographics, insurance status, type of
long-term care, and shift.
CONCLUSIONS: Behavioral, pharmacological, and medi-
cal treatments that successfully control or alleviate UI condi-
tions may yield substantial savings in long-term care set-
tings.
ECONOMIC AND OUTCOMES ISSUES OF 
INFECTIOUS DISEASES
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OBJECTIVES: To estimate the indirect costs of HIV and
AIDS for individuals in the United Kingdom based on uti-
lization of informal (non-medical) care and community
services; to compare these figures with direct costs; and to
demonstrate the multitude of budgets that are affected by
indirect costs.
METHODS: A prevalence-based model was used to deter-
mine the aggregate utilization by stage of progression (as-
ymptomatic HIV, symptomatic non-AIDS, AIDS). Sources
of data included SOPHID97 for prevalence figures; pub-
lished data by Petrou, et al. on service utilization and costs;
published figures from Lubeck and Fries and data from the
Positive Lives Employment Survey 1997 for disability; and
the UK Office of National Statistics Family Expenditure
Survey 1997–98 for disability and income data.
RESULTS: Annual indirect costs (converted to 1998 British
pounds) are £3,881.14 for asymptomatic HIV patients;
£7,865.17 for symptomatic non-AIDS patients; and
£21,695.13 for AIDS patients. These figures can be com-
pared to annual hospital direct cost figures published in
PharmacoEconomics in 1998, which were £2,391 for as-
ymptomatic HIV patients; £4,562 for symptomatic non-
AIDS patients; and £15,895 for AIDS patients. Thus, our
estimates of indirect costs are higher than the hospital direct
cost estimates for all three groups of HIV/AIDS patients.
CONCLUSIONS: The difference (in 1998 British pounds)
in annual indirect costs per patient between asymptomatic
and symptomatic non-AIDS patients is £3,984.03. The dif-
ference in annual indirect costs per patient between symp-
tomatic non-AIDS and AIDS patients is £13,829.96. These
differences demonstrate the potential for significant savings
if disease progression can be prevented or delayed. Focus on
indirect costs of HIV/AIDS demonstrates the complexity of
decision making when data is limited to direct medical costs
and raises an issue regarding who should have input into de-
cision making when multiple budgets are affected.
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OBJECTIVES: Lyme disease is an increasingly common
condition in the United States and temperate regions of
Europe and Asia. The reported cases have increased 25
fold since 1982. Recently two vaccines have been devel-
oped. Decisions about the cost effectiveness require consis-
tent cost estimates. The objective of this study is to identify
the costs of diagnosis, treatment, treatment failure, and
late diagnosis in a large HMO population located in an en-
demic area. Prior studies have not included the worried
well who are tested but do not receive treatment.
METHODS: This study is a matched retrospective cohort
study. 8,017 individuals tested or diagnosed with LD was
matched by age, gender, and zip code with a control popu-
lation. Standardized HMO and pharmacy costs were gath-
ered from the HMO claims system. Chronic disease status
was controlled using the Chronic Disease Score. Costs
were assessed for six weeks prior to first LD contact and
six weeks following first LD contact. Late-effect and treat-
ment failures were assessed separately for longer post-con-
tact windows. 
RESULTS: The mean 12 week per capita medical direct
expense for LD cases is 4.1 times higher than for the con-
trol group. The cost difference is highly significant (p 
0.001). Pharmacy expense is 1.77 times greater (p 
0.001).
CONCLUSIONS: The cost effectiveness of LD vaccines is
dependent on the identifying the cost of both treatment
and anxiety caused by the potential of tick-borne infec-
tion. The costs differences illustrated in this study empha-
size the importance of both true positives and the “wor-
ried-well” in assessing the total cost of LD to health
insurance sponsors.
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OBJECTIVES: The objective of this study was to measure
influenza-related hospitalization rates and cost in a man-
aged care population.
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METHODS: All subjects possessing an influenza diagno-
sis (ICD-9-CM  487) in PharMetrics’ Integrated Out-
comes Database between January 1, 1997 and June 30,
1998 were eligible for inclusion. Subjects with an influenza
diagnosis one-year prior to their index date and subjects
with less than 3 months of data available for analysis prior
to or following first diagnosis were excluded. Comorbidi-
ties, influenza vaccinations, antiviral and antibiotic pre-
scriptions were also identified during the study period.
RESULTS: A total of 18,000 subjects met all inclusion
criteria. The mean age of all subjects was 29.1 years (Std
Dev  20.7). Inpatient costs accounted for over 35% of
the $12.8 million in total costs incurred during the study
period, even though only 3% (472) of the sample required
hospitalization for influenza. The mean cost of an influ-
enza related hospitalization was $9,667 (Std Dev 
20,940) per subject hospitalized. Antibiotics were pre-
scribed in approximately 28% of the subjects, however an-
tivirals were prescribed to only (7%) of the subjects.
CONCLUSIONS: Although hospitalization for influenza
was rare (3%), the costs associated with this outcome
were significant. Prevention of hospitalizations related to
influenza could result in significant cost savings for man-
aged care organizations.
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OBJECTIVE: To assess the cost-effectiveness of pharma-
cotherapy for partners in a screening program for asymp-
tomatic infection with Chlamydia trachomatis (CT) in
women.
METHODS: A decision-analysis model was constructed
for the health outcomes of a CT screening program, such as
averted cases of pelvic inflammatory disease and infertility
(major outcomes). Prevalence estimates of CT-infection
and information on partner referral were derived from pi-
lot studies in Amsterdam (the Netherlands). Reinfection
due to failed partner referral or non-compliance with part-
ner pharmacotherapy was included in the model. Cost-
effectiveness from a societal perspective was estimated for a
screening program in General Practices in Amsterdam, di-
rected at women aged 15–29. For diagnosis of asymptom-
atic CT infection a Ligase Chain Reaction test on urine was
used, for pharmacotherapy of women and partners azithro-
mycin was used. By linking health outcomes with health-
care costs and productivity losses averted costs were esti-
mated. Cost-effectiveness was expressed as net costs per
major outcome averted and was calculated in the reference
case and in sensitivity analysis.
RESULTS: Partner pharmacotherapy induces reductions
of approximately 50% in net costs per major outcome
averted of the screening program. Within the broader
framework of the screening program partner pharmaco-
therapy is a cost-saving activity.
CONCLUSIONS: Inclusion of partner pharmacotherapy
provides significant improvements in overall cost-effective-
ness of the CT-screening program. Partner pharmacother-
apy lowers net costs per major outcome averted to realms
where implementation of the screening program for women
aged 15-29 should be considered. Implementation of the
program is currently discussed for the city of Amsterdam.
Given the cost-saving potentials, male partner pharmaco-
therapy should be pursued within broader framework of a
CT-screening program for women.
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The economic impact of administration of the extremely
expensive new amphotericin B (Amph B) preparations is
huge for Greek hospitals.
OBJECTIVE: The purpose of this study is to present the
cost of amphotericin B therapy and the cost-efficacy results,
after administration, of the three amphotericin prepara-
tions, available in the Greek market, in a third-grade univer-
sity hospital.
METHOD: 88 amphotericin prescriptions dispensed by
the Hospital Pharmacy were monitored over 2 months.
RESULTS:
1. The three preparations available in the hospital Phar-
macy are: A. Classic Amph B (Fungisone); B. Liposo-
mal Amph B (Am Bisome); C. Lipid-complexed Amph
B (ABLC). These are offered at the following prices (in
USD): A: 100 mg  1D, B: 100 mg  336D, C: 100
mg  106D
2. Duration of Amph B therapy: 18  3 days
3. Number of flacons per patient per day: Adults 5–12 fl;
Children: 5  1
4. Departments of major administration: Intensive Care
Units (Surgical-AIDS-Internal Medicine), Nephrology,
Pediatrics, Unit of Peritoneal Clearance
5. Cost of therapy: a. Costs per day, per patient A: 3D, B:
1680–3360D, C: 530–1060D. b. Costs of Total Ther-
apy per patient: A 30D, B 54.000  4.000 D. C.:
14.400  2.600 D
6. No clinical evidence has been provided yet, whether ad-
ministration of liposomal or lipid-complexed Amph B is
cost-effective and the optimum necessary dosage.
CONCLUSION: Extremely high costs for Amph B ther-
apy become a threat for Social Insurance, because hospi-
